Implementation of hfa-icos risk score in patients with non-hodgkin lymphoma undergoing non-pegylated doxorubicin therapy
Clicks: 1
ID: 323444
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #253 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Elderly patients with non-Hodgkin lymphoma, or patients with pre-existing cardiovascular comorbidities, are frequently treated with chemotherapy regimens containing non-PEGylated liposomal anthracycline, in order to reduce cardiotoxicity incidence. For patients candidate to anthracycline, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines recommend risk stratification through established proformas, but their real-world validation for patients candidate to liposomal anthracycline remains limited. Methods We retrospectively collected data on patients with newly diagnosed non-Hodgkin lymphoma treated with rituximab, cyclophosphamide, non-PEGylated doxorubicin, vincristine, and prednisone (R-COMP) between 2014 and 2025. Baseline demographics, cardiovascular history, echocardiographic and laboratory parameters, and baseline therapy were recorded. Patients were stratified into risk categories according to the Heart Failure Association International Cardio-Oncology Society (HFA-ICOS) score. Outcomes included overall survival (OS), cardiovascular events occurrence (including asymptomatic left ventricular dysfunction, new-onset or worsening heart failure and acute coronary syndrome) and progression-free survival (PFS). Results The cohort consisted of 265 patients [median age 73 years (69 – 77); 51% males]; 41% were classified as moderate risk, 55% as high risk, and 4% as very high risk. During a median follow-up of 29 months, 38 patients (14%) died. OS and cardiovascular events occurrence significantly differed across HFA-ICOS risk categories (p=0.005 and p<0.0001, respectively). Very high-risk patients exhibited substantially higher hazards of mortality (HR 5.8) and cardiovascular events (HR 40.4). Cardioprotective therapy at baseline did not influence cardiovascular outcomes. Conclusions The HFA-ICOS score effectively stratifies mortality and cardiotoxicity risk among R-COMP–treated patients. These findings support its application in routine treatment of lymphomas requiring anthracycline-based therapy.
| Reference Key |
openalex_W7172343199
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | M Camilli, I Torre, L Leo, M Viscovo, S Hohaus, F Burzotta, A Lombardo, G Minotti |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.049
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.